antisense oligonucleotide Archives

Antisense Oligonucleotides (ASOs)

Post author:David Cunnington
Post published:December 23, 2019
Post category:Podcast
Post comments:0 Comments

Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work?

Developing Treatment for SCN2A

Post author:SCN2A Australia
Post published:November 23, 2019
Post category:Webinar
Post comments:0 Comments

Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.

Webinar – Working towards SCN2A treatment

Post author:David Cunnington
Post published:November 21, 2019
Post category:
Post comments:0 Comments

Speakers: Prof. Steven Petrou, Director of the Florey and RogCon, Chief Scientific Officer, and Dr. Kiran Reddy, CEO of Praxis Precision Medicines. At the 2018 American Epilepsy Society meeting, Prof…

Developing Treatments for SCN2A

Post author:SCN2A Australia
Post published:November 10, 2019
Post category:Podcast
Post comments:0 Comments

We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.

SCN2A Australia

2 days ago

The Genetic Epilepsy Team Australia - GETA 2021 conference registrations have gone live. You can attend virtually or face to face in Melbourne - we hope will join us. ... See MoreSee Less

Genetic Epilepsy Family Conference 2021 run by GETA

www.eventbrite.com.au

In 2021 GETA will hold a hybrid event - with those who can and want to attend can do so face to face at the The Florey Institute.

View on Facebook

SCN2A Australia shared a video from the playlist SCN2A Virtual Conference 2021.

1 week ago

Watch this video by Prof. Steve Petrou from The Florey Institute of Neuroscience and Mental Health to learn more about Loss of Function presentations in SCN2A and what this means for potential treatments. #SCN2A #CureSCN2A #scn2aclinicaltrials #Aso #scn2aawareness ... See MoreSee Less

Video

View on Facebook